Bowel preparation is a major determinant of colonoscopy and colorectal surgery. Polyethylene glycol electrolyte solutions (PEG-E) are the most commonly used laxatives in China. However, a significant number of patients, especially those constipated patients, failed colonoscopies due to poor bowel cleaning. Inadequate preparation may also lead to missed colonic lesions. The study is based on the hypothesis: itopride hydrochloride, a prokinetic agent, its dual role as dopamine D2 receptor antagonism and acetylcho-linesterase inhibition make it an appropriate adjuvant for bowel preparation. It was reported to promote colonic peristalsis, shorten colonic transit time and accelerate propulsion of colonic luminal contents through inhibition of M3 receptor and dopamine D2 receptors in vitro and in vivo. So this study is to determine the efficacy, tolerance and safety of high dose of itopride, when given in different times before administration of PEG-E, for colonic preparation in patients with chronic constipation.
Full Title of Study: “High Dose of Itopride: a Valid Adjuvant for Bowel Preparation in Patients With Chronic Constipation”
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: Single (Outcomes Assessor)
- Study Primary Completion Date: November 2011
Colonoscopy is a reliable procedure for the investigation of colonic and distal terminal ileum disease. The diagnostic accuracy of colonoscopy is dependent on visualization of the colonic mucosa; hence an appropriate bowel preparation is essential for the examination. Despite multiple lavage were used throughout the years, the suboptimal cleaning level have been reported vary from 10% to more than 20% and up to one-third of incomplete or failed colonoscopies can be ascribed to poor bowel preparation. So it is important for us to search a new regimen for bowel preparation.
- Drug: Polyethylene glycol electrolyte solutions
- Patients received 2 packets of polyethylene glycol electrolyte solutions(PEG-E) without itopride.PEG-E was dissolved in 2 L of water. Patients were instructed to drink PEG solution 200ml every 10 min consumed the total 2 L solution in 2 hours.6 hours later, the colonoscopy was performed.
- Drug: Itopride and Polyethylene glycol electrolyte solutions
- Patients were assigned to itopride 150mg, then 30 min later they were given 2 packets of polyethylene glycol electrolyte solutions(PEG-E). PEG-E was dissolved in 2 L of water. Patients were instructed to drink PEG solution 200ml every 10 min consumed the total 2 L solution in 2 hours. 6 hours later, the colonoscopy was performed.
- Drug: itopride and polyethylene glycol electrolyte solutions
- Patients received itopride 150mg t.i.d(7am、12am、8pm) 24 hours before the examination day and another 150mg 30min before administration of polyethylene glycol electrolyte solutions(PEG-E).Two packets of PEG-E were dissolved in 2 L of water. Patients were instructed to drink PEG solution 200ml every 10 min and consumed the total 2 L solution in 2 hours. 6 hours later, the colonoscopies were performed.
Arms, Groups and Cohorts
- Active Comparator: group PEG
- This group is set as a control group and received 2 packets of Polyethylene glycol electrolyte solutions on the morning of the examination day as us we usually done.
- Active Comparator: group PEG+Itp
- Patients in group were assigned to itopride half hour before administration of lavage solution in the morning of examination day.
- Active Comparator: group PEG+4Itp
- Patients in this group received itopride three times 24 hours before the examination day and another time 30 min before administration of lavage solution.
Clinical Trial Outcome Measures
- the quality of bowel preparation
- Time Frame: the day of colonoscopy examination
- the Boston Bowel Preparation Scale (BBPS): the colon was divided into 3 broad segments: the right side (the cecum and ascending colon), the middle section (the hepatic ﬂexures, transverse colon and splenic ﬂexures), and the left side of the colon (the descending colon, sigmoid colon, and rectum). Each region of the colon receives a score from 0 to 3 as summarized in table 1, score 0 was considered poor preparation while score 3 indicated good cleaning quality. And these segment scores are summed for a total BBPS score ranged from 0 to 9.
- intestinal bubble scale
- Time Frame: the day of colonoscopy examination
- The scores of intestinal bubble were categorized into three levels: 0, no or nearly no bubble present; 1, small amounts of bubbles that could be washed away easily; 2, multiple collections of bubbles that could be washed away with volumes of water.
- time of examination
- Time Frame: the day of examination
- Time of examination includes caecal intubation time and withdrawal time. Caecal intubation time deﬁned as the time passing the colonoscope to the ileocaecal valve. Withdrawal time deﬁned as the time withdrawing from ileocaecal junction to anus.
- times of defecation
- Time Frame: the day before and the day of examination
- The times of defecation during the preparation were obtained and analyzed.
Participating in This Clinical Trial
- Patients suspected colonic disease and suffered from chronic constipation were referred for colonoscopy and enrolled in the study. Chronic constipation was diagnosed on the basis of Rome III criteria.Suspected colonic disease was deﬁned as: – recent change of bowel habits; – obscure GI bleeding (hemafecia, melena or positive fecal occult blood test); – obscure abdominal pain; – weight loss; – positive ﬁndings in the colon on GI imaging; – serological test referred to colorectal cancer such as CEA elevated obviously; – family history of colorectal cancer or adenomatous polyps. Exclusion Criteria:
- usage of prokinetic agents such as itopride, mosapride within 4 weeks and tricyclic antidepressants 8 weeks prior to entering the protocol; – known allergies or other contraindication to PEG or itopride; – a history of abdominal surgery or bowel obstruction; – pregnant or lactating; – conditions associated with severe cardiac, hepatic, or renal impairment.
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 75 Years
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Provider of Information About this Clinical Study
- Principal Investigator: Xiaobo Li, Xiaobo Li – Shanghai Jiao Tong University School of Medicine
- Overall Official(s)
- Li X B, M.D., Ph.D., Study Chair, Shanghai Jiao-Tong University School of Medicine Renji Hospital
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.